Skip to main content
Signal8

ICON PLC (ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Sector: Services-Commercial Physical & Biological Research

Industry: Medical - Diagnostics & Research

ICON Public Limited Company logo

ICON Public Limited Company

NASDAQ:ICLRHealthcare
-1.91%$211.36
AH$211.36+0.00%vs close
Mkt Cap$15.83B
Float75.95M
O/S74.92M
Vol
$ Vol
RVOL
Inst Own-
SI3.9%
Earnings
Dilution
Phase Distribution
5 lead-sponsored trials·0 active·3 completed
Phase 23
Phase 32
(99 more as collaborator)
Status Overview
Completed3
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

    IBI-10090, Placebo

    Inflammation, Cataracts

    Enrollment
    394
    Start
    Jan 2014
    Primary Completion
    Oct 2014
    Completion
    Oct 2014
    NCT02006888
  • Phase 3
    Completed

    Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

    Dexamethasone, Prednisolone

    Cataract

    Enrollment
    194
    Start
    Nov 2015
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02547623
  • Phase 2
    Terminated

    Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

    IBI-10090

    Inflammatory Reaction Due to Ocular Lens Prosthesis

    Enrollment
    6
    Start
    Jan 2010
    Primary Completion
    May 2010
    Completion
    Jun 2010
    NCT01048593
  • Phase 2
    Terminated

    Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

    IBI-10090

    Ocular Inflammation

    Enrollment
    42
    Start
    Oct 2010
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01214174
  • Phase 2
    Completed

    Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

    IBI-10090

    Inflammation Associated With Cataract Surgery

    Enrollment
    172
    Start
    Apr 2012
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT01606735